ClinicalTrials.gg
RecruitingNCT07867405Updated Oct 9, 2026

The Effect of Tail Fat Application on Joint Pain, Joint Stiffness, and Daily Living Activities in Patients With Gonarthrosis

An interventional study of Sheep Tail Fat and Standard medical treatment in Gonarthrosis, sponsored by Inonu University. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Inonu University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2026, registered Sep 2026).
  • Started May 2026; still recruiting 5 months later.
Updated Oct 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In recent years, experimental and clinical studies conducted on sheep tail fat, a natural and easily accessible resource, have shown that bioactive components found in sheep tail fat, such as palmitic acid, stearic acid, oleic acid, linoleic acid, and myristic acid, have anti-inflammatory and chondroprotective (cartilage-protective) properties. In addition, literature reviews have revealed that sheep tail fat alleviates joint pain and has a positive effect on joint stiffness. Sheep tail fat is known to be frequently used by patients with gonarthrosis (knee osteoarthritis) in Türkiye and many other countries as a traditional and complementary medicine method.

In this context, this study is designed as a randomized controlled experimental study to evaluate the effects of sheep tail fat application on pain, joint stiffness, and activities of daily living in patients with gonarthrosis. The study population consists of patients diagnosed with gonarthrosis who apply to the Physical Therapy and Rehabilitation outpatient clinics of two state hospitals located in Bitlis. According to the sample size calculation performed using G*Power 3.1.9.7 software, a total of 66 participants were determined and randomly assigned to the experimental and control groups. Participants in the experimental group will receive topical sheep tail fat application in addition to standard medical treatment, while the control group will continue to receive standard medical treatment only.

Data collection tools include the Patient Identification Form developed by the researcher, the Visual Analog Scale (VAS) for assessing pain intensity, and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for assessing pain, joint stiffness, and daily physical function. These scales will be administered at baseline and again after completion of the intervention period.

The double-boiler (bain-marie) method is used to obtain the sheep tail fat, and participants are provided with training on the application techniques. The required ethics committee approval and institutional permissions from the relevant healthcare institutions have been obtained, and written informed consent has been obtained from all participants. Hamdani sheep, one of the sheep breeds commonly raised and traditionally preferred in the region where the study is conducted, are used to obtain the sheep tail fat.

For the statistical analysis of the data, in addition to descriptive statistics, the paired-samples t-test or Wilcoxon signed-rank test will be used for within-group comparisons, while the independent-samples t-test or Mann-Whitney U test will be used for between-group comparisons. When the assumptions of parametric tests are not met, appropriate non-parametric methods will be preferred.

This study aims to contribute scientifically to clinical decision-making processes regarding traditional and complementary treatment approaches by evaluating, within an evidence-based framework, the effectiveness of a method traditionally used for the management of gonarthrosis symptoms in many countries. It also aims to support the standardization of traditional, complementary, and alternative medicine practices and to provide scientific evidence regarding a low-cost, natural, non-invasive, and accessible alternative treatment option. In addition, the findings are expected to guide the development of new strategies to improve functional well-being in patients with gonarthrosis.

02

Conditions studied

  • Gonarthrosis

Keywords

  • gonarthrosis
03

In context

Osteoarthritis, Knee

3,391 studies on the registry are indexed under Osteoarthritis, Knee; 628 are open to participants now.

This study's planned enrollment of 66 is close to the median of 69 across 2,808 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Inonu University is the lead sponsor of 384 studies on the registry; 90 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria**

  • Patients diagnosed with gonarthrosis by a physician.
  • Patients with a VAS score above 4.
  • Individuals who have experienced pain related to knee osteoarthritis for at least the last 3 months.
  • Participants aged 18 years and older.
  • Individuals without an allergy to sheep tail fat or other animal products.
  • Individuals who can communicate in Turkish and understand written and verbal instructions.
  • Individuals who can apply the sheep tail fat according to the instructions.
  • Individuals who agree to participate in the study.

**Exclusion Criteria**

  • Individuals with severe physical disability or mental/psychological problems in the knee region.
  • Individuals with intellectual or cognitive limitations.
  • Individuals who have undergone knee surgery within the last year.
  • Individuals with peripheral vascular disease.
  • Individuals with infection, wound, cellulitis, or active skin disease in the knee region.
  • Individuals who have experienced knee trauma or received an intra-articular steroid injection within the last six months.
  • Individuals diagnosed with secondary arthritis or inflammatory joint disease.
  • Pregnant or breastfeeding women.
  • Individuals with active bleeding disorders.
  • Individuals with asthma and individuals with liver or kidney failure.
  • Individuals with connective tissue diseases (e.g., lupus, systemic sclerosis).
  • Individuals who have experienced a serious infection within the last three months or are immunosuppressed.
  • Individuals with neurological diseases affecting knee stability.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Experimental Group(Sheep Tail Fat + Standard Treatment)

    Participants in this group will receive topical sheep tail fat application in addition to standard medical treatment.

    Other: Sheep Tail Fat

  • Active comparator
    Control Group(Standard Medical Treatment)

    Participants in this group will receive standard medical treatment only.

    Other: Standard medical treatment

Interventions

  • OtherSheep Tail Fat

    Topical application of sheep tail fat to the knee once daily for two weeks, seven days per week, with each application lasting at least three hours.

  • OtherStandard medical treatment

    Participants in the control group will receive standard medical treatment only.

06

What researchers measure

Primary outcomes

  1. Pain intensity measured by the Visual Analog Scale (VAS)

    Pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, with higher scores indicating greater pain intensity.

    Time frame: Baseline and 2 weeks

07

Study locations

2 of 2 sites recruiting
  • Bitlis State Hospital
    Bitlis, Turkey (Türkiye)
    Recruiting
  • Bitlis Tatvan State Hospital
    Bitlis, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07867405
Lead sponsor
Inonu University
Responsible party
Medet Korkmaz (Professor, Inonu University) — Principal investigator
First posted
Oct 9, 2026
Start date
May 12, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Medet KORKMAZ
Contact
medet.korkmaz@inonu.edu.tr
05065027980
Medet KORKMAZ
study director · Inonu University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion